Uniquely measures serum infliximab (IFX) and antibodies to infliximab (ATI) levels at any time

Monitoring your inflammatory bowel disease (IBD) patients may help you address IFX therapy challenges

Development of ATI has been associated with poor clinical outcomes
- 60% of IFX-treated pediatric IBD patients who underwent bowel surgery were ATI-positive (≥ 12 U/mL) vs only 8% positivity in patients who did not have surgery ($P = 0.01$)$^2$.
- ATI-positive IBD patients had higher likelihood of losing response to IFX than patients without ATI (pooled risk ratio = 3.2; $P < 0.0001$)$^3$.

IFX drug level may affect outcomes
- IFX level of ≥ 5 μg/mL was associated with a longer duration on maintenance IFX therapy without flares ($P < 0.0001$)$^5$.
- Recent American Gastroenterological Association guidelines recommend using therapeutic drug monitoring for patients who have lost response to IFX (therapeutic target for IFX: ≥ 5 μg/mL)$^6$.

The PROMETHEUS® Anser® Test
heritage of excellence

- Proven use in multiple clinical studies$^5$.$^7$.$^13$
- More cost-effective than empiric management for managing loss of response to IFX$^4$
- Confidence of over 100,000 patient experiences since 2012

Learn more at anserifx.com

*In a cross-sectional study of 134 pediatric and young adult patients where serum IFX and ATI levels were reported based off PROMETHEUS® Anser® IFX Test.
**From a meta-analysis of 13 studies with reported results from 1,378 patients where serum IFX and ATI levels were reported based off enzyme-linked immunosorbent assays (ELISA).
***In a retrospective, dose-adjustment study of 126 IBD patients where serum IFX levels were reported based off Anser® IFX and ELISA.
Uniquely measures serum adalimumab (ADA) and antibodies to ADA (ATA) levels at any time

Developing ATA has been associated with poor clinical outcomes

- A significantly higher proportion of ADA patients who did not achieve mucosal healing (MH) had high-titer ATA (>1 U/mL).5
- The presence of ATA > 0.55 U/mL has been associated with lower ADA and higher C-reactive protein (CRP) levels.6

ATA were more likely to be present when ADA levels were < 7.5 μg/mL.7

ADA drug level may affect outcomes

- ADA level of 7.5 μg/mL has been associated with endoscopic healing (EH).8
- Recent American Gastroenterological Association guidelines recommend using therapeutic drug monitoring for patients who have lost response to ADA (therapeutic target for ADA: ≥ 7.5 μg/mL)

References:
20. PROMETHEUS, the Link Design. For the person in every patient, Anser, and the Anser design mark are registered trademarks of Société des Produits Nestlé S.A. Vevey, Switzerland. ©2018 Société des Produits Nestlé S.A. Vevey, Switzerland. All rights reserved. ADA18003 02/18

A Nestlé Health Science Company
Prometheus diagnostic services provide important information to aid in the diagnosis and management of certain diseases and conditions. How this information is used to guide patient care is the responsibility of the physician.

Assays and methods within these tests may be covered by one or more US pending or issued patents. For details, please go to www.prometheuslabs.com.